After revising other clinical baseline characteristics, including age, sex, T stage, N stage, tumour stage and expression of Ki-67, the serum miRNA-29a and miRNA-125b before treatment and miRNA-26b after treatment in combination were independent prognostic factors for PFS (high-risk groups vs low-risk groups, hazard ratio [HR] 3.149, 95% CI 1.088–9.115, p = 0.034) (Table 4). Here, MKI67 is linked to neoplasm.